South Africa Rolls Out Game-Changing HIV Prevention Shot

South Africa is about to make history in the fight against HIV with a medical breakthrough that works almost perfectly.

In just days, public clinics across the country will begin offering lenacapavir, an injection that prevents HIV infection for six months at a time. The shot proved nearly 100% effective in major clinical trials, earning recognition as Science magazine's 2024 scientific breakthrough of the year.

For a country where more than 140,000 people still contract HIV each year, this changes everything. Unlike daily prevention pills that require perfect memory and commitment, lenacapavir only asks people to return to a clinic twice a year.

The timing couldn't be better. South Africa's HIV treatment program has slowed its growth, meaning the pool of people who can transmit the virus remains stubbornly large. Meanwhile, daily prevention pills have been available for years but only a few hundred thousand people take them regularly.

Lenacapavir solves the consistency problem. Injected just under the skin, usually in the stomach area, it creates a tiny depot that slowly releases the drug over six months. The most common side effects are minor: injection site pain, skin rash, and small harmless lumps under the skin that typically shrink with each dose.

The rollout includes two groups often left out of HIV research: teenagers aged 16 and 17, and pregnant women. Clinical trials proved the injection safe for both, opening protection to some of the most vulnerable populations.

About half a million South Africans will gain access to this prevention method in the initial rollout. Before their first injection, people will take an HIV test to ensure they don't already have the virus, since using lenacapavir alone to treat existing HIV could create drug resistance. They'll also take lenacapavir tablets for two days alongside their first shot to quickly build up drug levels in their body.

This represents a massive leap forward from earlier long-acting options. Another prevention injection called CAB-LA provides two months of protection and showed promise in 2020, but South Africa's government found the manufacturer's prices too high for widespread use.

The Ripple Effect

The impact of lenacapavir extends far beyond individual protection. When fewer people contract HIV, fewer people can transmit it, creating a virtuous cycle that could finally bend the curve on new infections. For people who face stigma around taking daily HIV pills, the injection offers discrete protection. For those juggling work, family, and life's daily chaos, it removes the burden of perfect adherence.

South Africa's HIV epidemic has come a long way from its darkest days, but the virus still takes more than 50,000 lives each year. Condoms and daily prevention pills remain important tools, but they haven't been enough to dramatically reduce new infections.

Now there's real hope for change. A twice-yearly injection that works almost perfectly could protect millions of people who've struggled with daily pills or simply want a more convenient option.

South Africa is leading the world into a new era of HIV prevention, one injection at a time.